Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas

References

• Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23. doi:10.1136/ard.2004.033217
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-3
   PubMed Web of Science ®Google Scholar
• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi:10.1111/bjd.18245
   PubMed Web of Science ®Google Scholar
• Oliveira MD, Rocha BD, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. doi:10.1590/abd1806-4841.20153038
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488. doi:10.3390/ijms21207488
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• Furue K, Ito T, Tsuji G, Kadono T, Furue M. Psoriasis and the TNF/IL23/IL17 axis. G Ital Dermatol Venereol Organo Uff Soc Ital di dermatologia e Sifilogr. 2019;154(4):418–424. doi:10.23736/S0392-0488.18.06202-8
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22:355–362. doi:10.1080/14740338.2023.2218086
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):365–372. doi:10.1080/14740338.2020.1730326
   PubMed Web of Science ®Google Scholar
• Reich K, Iversen L, Puig L, et al. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and −3. J Eur Acad Dermatol Venereol. 2022;36(8):1275–1283. doi:10.1111/jdv.18068
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6(2):111–124. doi:10.1007/s13555-016-0121-x
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi:10.1056/NEJMoa1503824
   PubMed Web of Science ®Google Scholar
• Mastorino L, Cariti C, Susca S, et al. Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks. J Dermatolog Treat. 2022;33(8):3211–3213. doi:10.1080/09546634.2022.2125265
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299–1310. doi:10.1080/14712598.2021.1941862
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35:e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi:10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar
• Nicolescu AC, Ionescu MA, Constantin MM, et al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness. Life. 2022;12(12):2050. doi:10.3390/life12122050
   PubMedGoogle Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Pourani MR, Abdollahimajd F, Zargari O, Shahidi Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J Dermatolog Treat. 2022;33(4):1967–1974. doi:10.1080/09546634.2021.1966357
   PubMed Web of Science ®Google Scholar
• Cacciapuoti S, Ruggiero A, Gallo L, Fabbrocini G. Proactive vs. reactive psoriasis therapy: a long-term evaluation with dermoscopic and confocal microscopy assessment. Eur Rev Med Pharmacol Sci. 2022;26(6):2018–2024. doi:10.26355/eurrev_202203_28350
   PubMed Web of Science ®Google Scholar
• Golińska J, Sar-Pomian M, Rudnicka L. Dermoscopy of plaque psoriasis differs with plaque location, its duration, and patient’s sex. Ski Res Technol off J Int Soc Bioeng Ski. 2021;27(2):217–226. doi:10.1111/srt.12933
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother. 2018;19(6):561–575. doi:10.1080/14656566.2018.1448788
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Mason MA, Gordon K, et al. Characterization of patients with psoriasis in challenging-to-treat body areas in the corrona psoriasis registry. Dermatology. 2021;237(1):46–55. doi:10.1159/000504841
   PubMed Web of Science ®Google Scholar
• Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi:10.1111/dth.12589
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Iversen L, Rasmussen MK, Kofoed K, Skov L, Zachariae C. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332–337. doi:10.1111/bjd.17689
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1–12. doi:10.3390/ijms21051690
   Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34:e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. Dermatol Ther. 2022;12(6):1289–1302. doi:10.1007/s13555-022-00746-6
   PubMed Web of Science ®Google Scholar
• Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2022;33(1):261–265. doi:10.1080/09546634.2020.1749546
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a Phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52. doi:10.1016/j.jdermsci.2015.10.009
   PubMed Web of Science ®Google Scholar
• Yadav K, Singh D, Singh MR. Protein biomarker for psoriasis: a systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis. Int J Biol Macromol. 2018;118(Pt B):1796–1810. doi:10.1016/j.ijbiomac.2018.07.021
   PubMedGoogle Scholar
• Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(6):700–711. doi:10.1111/jdv.12257
   PubMed Web of Science ®Google Scholar
• Malecic N, Young HS. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis. Expert Opin Investig Drugs. 2016;25(4):455–462. doi:10.1517/13543784.2016.1153064
   PubMed Web of Science ®Google Scholar
• Wang ZY, Fei WM, Li CX, Cui Y. Comparison of dermoscopy and reflectance confocal microscopy accuracy for the diagnosis of psoriasis and lichen planus. Ski Res Technol off J Int Soc Bioeng Ski. 2022;28(3):480–486. doi:10.1111/srt.13158
   PubMed Web of Science ®Google Scholar
• Errichetti E, Stinco G. Dermoscopy in general dermatology: a practical overview. Dermatol Ther. 2016;6(4):471–507. doi:10.1007/s13555-016-0141-6
   PubMed Web of Science ®Google Scholar
• Lallas A, Kyrgidis A, Tzellos TG, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea. Br J Dermatol. 2012;166(6):1198–1205. doi:10.1111/j.1365-2133.2012.10868.x
   PubMed Web of Science ®Google Scholar